Table 4.
Evaluation of CA 125 and ROMA efficiency in the diagnosis of ovarian cancer (excluding other gynaecological malignancies) according to HE4 results (> or <150 pmol/L)
| PPV | PPV in premenopausal women | PPV in postmenopausal women | ||
|---|---|---|---|---|
| HE4 >150 pmol/L | CA 125+ ROMA+ | 75/77 (97.4%) | 13/13 (100%) | 62/64 (96.9%) |
| CA 125− ROMA+ | 13/13 (100%) | 4/4 (100%) | 9/9 (100%) | |
| CA 125+ ROMA− | – | – | – | |
| CA 125− ROMA− | 0/1 (0%) | – | 0/1 (0%) | |
| HE4 <150 pmol/L | CA 125+ ROMA+ | 12/22 (54.5%) | 3/8 (37.5%) | 9/14 (64.3%) |
| CA 125− ROMA + | 0/23 (0%) | 0/20 (0%) | 0/3 (0%) | |
| CA 125+ ROMA− | 5/76 (6.6%) | 4/69 (5.8%) | 1/7 (14.3%) | |
| CA 125− ROMA− | 6/184 (3.3%) | 3/139 (2.2%) | 3/45 (6.7%) | |
PPV positive predictive value